arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

4D Molecular Therapeutics, Inc.

FDMT
$10.77 ▲ +0.22 (+2.09%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

4D Molecular Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $733.1M
Dividend Yield
Revenue Growth 21664.3%
Op. Margin None
ROIC -12.9%
FCF / Share $-1.00
Trailing P/E
Price / Book 1.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.05M
↑ +21664.3%
Net Income Profit after all expenses
$-68.76M
↓ -43.3%
Operating Margin Operating profit as % of sales
17.3%
↑ +125.0% 0th
FCF / Share Free cash flow per share
$-1.00
↓ -15.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
24
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters